NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda, stating the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. The company emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
According to the press release, NV-387 is designed to target viral cell attachment pathways that are common among filoviruses, including Ebola. This mechanism could provide a broad-spectrum effect against multiple strains. The company believes that if NV-387 proves effective, it could serve as a critical tool for pandemic preparedness, especially given the limited treatment options currently available for Ebola virus disease.
NanoViricides is advancing NV-387 into Phase II human clinical trials for respiratory viral infections such as RSV, COVID-19, and influenza, but the drug candidate is also being investigated for other viral diseases, including MPOX, smallpox, and measles. The company has developed NV-387 as an oral drug, which could offer advantages in terms of administration and patient compliance compared to injectable treatments.
The Bundibugyo Ebola outbreak, which began in 2024, has raised concerns about the need for effective antiviral treatments. Current therapies for Ebola are limited to monoclonal antibodies and supportive care. NV-387’s oral formulation and potential broad-spectrum activity could fill a significant gap in the antiviral armamentarium.
For more details on the announcement, view the full press release here. Additional information about NanoViricides and its pipeline is available on the company’s website at www.nanoviricides.com.
The company notes that drug development is a lengthy and capital-intensive process, and there can be no assurance that NV-387 will demonstrate sufficient safety and efficacy in clinical trials. However, the potential for a broad-spectrum oral antiviral against Ebola and other filoviruses underscores the importance of continued research and development in this area.
